Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Moderna Inc
MRNA
Healthcare
Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or...
preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:MRNA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(45)
•••
MarketWolf2024
X
Post by
MarketWolf2024
on Jan 08, 2025 4:11pm
Moderna dips as bird flu death sparks vaccine focus
Moderna's stock surged over 10% after the first U.S. bird flu death, highlighting the company's H5N1 vaccine development.
(11)
•••
ssomervst
X
Comment by
ssomervst
on Jan 02, 2025 10:59am
RE:Oversold. Over beaten.
Agreed, this is a $75 stock any day of the week. $21 per share in cash on the books with no debt. Impressive pipeline with several products in stage 3. Let's not forget bird flu looking like it
...more
(123)
•••
ecolo101
X
Post by
ecolo101
on Dec 14, 2024 9:57am
Oversold. Over beaten.
Way too much potential, it is just a question of Time for the sector. when it Will turn, it Will go back up quickly. glta dyodd
(14)
•••
IronFocus77
X
Post by
IronFocus77
on Dec 06, 2024 2:49pm
MRNA Ascending Triangle Long Setup on the Downtrend!
Spotted a clean ascending triangle on the downtrend. Breakout above $46 and EMA200 = long play. Entry: $46.4, Stop: $42.5, Target: $57. Anyone else watching this setup?
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 25, 2024 7:02am
New Press Release - Moderna to Present at Upcoming Conferences in December 2024
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ETPiper Sandler 36th Annual Healthcare Conference, on...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 12, 2024 8:20am
New Press Release - Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation."We are honored to be recognized by BioSpace as the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 08, 2024 7:32am
New Press Release - Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringesCanada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and QatarCAMBRIDGE, MA / ACCESSWIRE / November 8, 2024...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 08, 2024 7:30am
New Press Release - Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC)PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 07, 2024 6:43am
New Press Release - Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 05, 2024 9:05am
New Press Release - Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumorsPHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 03, 2024 12:27pm
New Press Release - Shareholder Notice to Long-Term Shareholders of Moderna, Inc. (MRNA)
Philadelphia, Pennsylvania--(Newsfile Corp. - November 3, 2024) - Grabar Law Office is investigating whether officers and directors of Moderna, Inc. (NASDAQ: MRNA) breached their fiduciary duties owed to the company. If you have held Moderna shares since prior to January 18, 2023, and would like...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 31, 2024 7:01am
New Press Release - Moderna to Present at Upcoming Conferences in November 2024
CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Guggenheim's Inaugural Healthcare Innovation Conference, on Tuesday, November 12th at 10:00am ETUBS Global Healthcare Conference, on...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 28, 2024 6:45am
New Press Release - Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the investigational individualized neoantigen therapy, V940 (mRNA-4157), focused on earlier stages of cancer Merck (NYSE: MRK), known as MSD outside of the United...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 24, 2024 2:26pm
New Press Release - Moderna Named a Top Employer by Science for Tenth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 23, 2024 8:00am
New Press Release - Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
CAMBRIDGE, Masss. and LONDON, Oct. 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Junaid Bajwa, M.D., has joined its London office as Senior Partner and Head of United Kingdom. In this role, Dr. Bajwa will play an integral role in advancing...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Healthcare and Clinical Stage Drug Development Company Acquires NoBrainer Imaging Centers